CapsoVision, Inc (CV) Q3 2025 10-Q Quarterly Report
Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Electromedical & Electrotherapeutic ApparatusSEC EDGAR CapsoVision, Inc (CV) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
CapsoVision, Inc Q3 2025 10-Q Analysis
Risk Factors
- • New risk: FDA Breakthrough Device Designation submitted for pancreatic cancer capsule endoscopy solution Nov 6, 2025, uncertain eligibility and authorization timing
- • Updated regulatory risk: Potential delays in FDA 510(k) clearance for CapsoCam Colon second-generation due to FDA staff reductions and government shutdowns still unresolved
CapsoVision, Inc Q3 2025 Quarterly FinancialsXBRL
Revenue
$4M
▼ -42.0% QoQ
Net Income
-$8M
▲ +20.8% QoQ
Gross Margin
54.1%
▼ -10bp QoQ
Operating Margin
-226.7%
▼ -6212bp QoQ
Net Margin
-223.9%
▼ -5990bp QoQ
ROE
-38.7%
Total Assets
$26M
EPS (Diluted)
$3.44
▲ +176.6% QoQ
Operating Cash Flow
-$6M
▲ +40.4% QoQ
Source: XBRL data from CapsoVision, Inc Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on CapsoVision, Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.